Form 4: MindMed CEO Robert Barrow Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
MindMed's CEO, Robert Barrow, sold 16,519 common shares on March 25, 2024, to cover withholding tax obligations related to vested restricted stock units.
Summary
- Robert Barrow, the CEO of Mind Medicine (MindMed) Inc., sold 16,519 common shares on March 25, 2024.
- The sale was executed to satisfy withholding tax obligations related to the settlement of vested restricted stock units.
- The shares were sold at a weighted average price of $9.5, with individual transactions ranging from $9.37 to $9.55.
- Following the transaction, Barrow beneficially owns 580,202 common shares.
- Barrow has a Rule 10b5-1 plan adopted on June 15, 2022.
- Barrow has granted power of attorney to the Chief Executive Officer, Chief Financial Officer, Chief Legal Officer and Associate General Counsel of Mind Medicine (MindMed) Inc. to execute forms 3, 4, and 5.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sale of shares to cover tax obligations) by the CEO, which is neither particularly positive nor negative. The existence of a 10b5-1 plan suggests the transaction was pre-planned.
Industry Context
This is a routine transaction related to executive compensation and tax obligations. It is common for executives to sell shares to cover taxes when restricted stock units vest. The existence of a 10b5-1 plan suggests the transaction was pre-planned and not based on any inside information.
Comparison to Industry Standards
- Executive stock sales for tax purposes are a common practice across publicly traded companies.
- Companies like Pfizer, Johnson & Johnson, and Merck often see similar transactions from their executives.
- The use of Rule 10b5-1 plans is a standard method to ensure compliance with insider trading regulations, as seen in companies like Tesla and Apple.
Stakeholder Impact
- The sale of shares by the CEO could have a minor, temporary impact on the stock price, but is unlikely to be significant given the relatively small number of shares sold and the pre-planned nature of the transaction.
- The transaction does not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| June 15, 2022 | Date of adoption of Rule 10b5-1 plan |
| March 25, 2024 | Date of the share sale transaction |
| March 26, 2024 | Date of the signature of the attorney-in-fact for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.